Table 4

Association of SREBP-2 haplotypes between the AVN patients and controls

Haplotype
Genotype
Controls (%)
Patients (%)
Codominant

Dominant

Recessive






OR (95% CI)
P*
OR (95% CI)
P*
OR (95% CI)
P*

ht1
ht1/ht1
51 (19.03)
73 (16.67)
0.78
(0.624–0.975)
0.029
0.672
(0.481–0.94)
0.020
0.799
(0.536–1.192)
0.272
(G-G)
ht1/-
143 (53.36)
209 (47.72)







-/-
74 (27.61)
156 (35.62)






ht2
h2/ht2
15 (5.6)
53 (12.1)
1.245
(0.981–1.581)
0.071
1.128
(0.83–1.534)
0.440
2.238
(1.231–4.069)
0.008
(G-A)
ht2/-
122 (45.52)
131 (48.88)
184 (42.01)
201 (45.89)






ht3
ht3/ht3
16 (5.97)
31 (7.08)
1.081
(0.842–1.388)
0.542
1.068
(0.783–1.456)
0.678
1.245
(0.663–2.336)
0.495
(T-G)
ht3/-
105 (39.18)
168 (38.36)







-/-
147 (54.85)
239 (54.57)







Haplotypes; rs2269657, rs1052717

*Logistic regression analyses were used for calculating. bold: P value < 0.05

Kim et al. BMC Medical Genetics 2008 9:94   doi:10.1186/1471-2350-9-94